Clinical Trial · NCT02805608

uPAR PET/CT and FDG PET/MRI for Preoperative Staging of Bladder Cancer

Overview

The sensitivity and specificity of uPAR PET/CT with the radioligand 68GaNOTA-AE105 and FDG PET/MRI for preoperative detection of regional lymph node metastases in urinary bladder cancer

Phase

Phase 2

Contacts

Dorthe Skovgaard, Md, PhD (PRINCIPAL_INVESTIGATOR)

ClinicalTrials.gov

NCT02805608

Drug / Compound

FDG

Isotope(s):
Target(s):
  • Glucose Transport
Ligand Class: Small Molecules

AE105

Isotope(s):
Target(s):
  • uPAR
Ligand Class: Peptides
Chelator: NOTA

Eligibility

Inclusion

  • Biopsy-verified urinary bladder cancer

Exclusion

  • Treatment with neoadjuvant chemotherapy
  • Pregnancy
  • Known allergy towards 68Ga-NOTA-AE105
  • Weight above 140 kg
  • Lactation/breast feeding